Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.
“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so,” the company said in a statement.
AstraZeneca announced on Wednesday it had “voluntarily paused” its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step.
The committee “has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume”, AstraZeneca said.AstraZeneca’s vaccine candidate is one of nine around the world currently in late-stage Phase 3 human trials.
After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected.“AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials,” Saturday’s statement read.